Quebec–based Bausch + Lomb received FDA marketing clearance for its Stellaris Elite vision enhancement system, the company's next generation phacoemulsification cataract platform.

The device combines aspiration control with predictive infusion management for efficient cataract lens removal.

The company plans to release retina applications for the Stellaris Elite this summer, which will integrate retina and cataract capabilities into a single machine.

The system will also include the new Vitesse technology, a high-speed vitreous cutter, which is currently under FDA review. — Cynthia Jessup